Navigation Links
Delcath Systems to Host Quarterly Update Conference Call

NEW YORK, Dec. 30 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Company will host its quarterly update conference call at 4:30 PM Eastern Time on Thursday, January 22, 2009. Richard Taney, President and Chief Executive Officer of Delcath Systems, will host the call. Mr. Taney will discuss the progress of patient enrollment and the advancement of clinical studies. A question and answer session will immediately follow management's prepared remarks.


Joining Mr. Taney on the call will be Mark Morrison, MD, PhD, Chief Medical Officer; Jonathan Foltz, Executive Vice President; John Talarico, Senior Vice President Regulatory Affairs and Quality Systems; and Jason Rifkin, Senior Vice President Clinical Operations. Mr. Taney will also introduce Barbra Keck, Delcath's recently hired Controller. Ms. Keck will assume the responsibilities of Principal Accounting Officer following the previously announced departure of Delcath's Chief Financial Officer.

Mr. Taney commented, "2008 was a transformational year for Delcath. We expanded our pivotal Phase III FDA trial from our base at the National Cancer Institute to 10 regionally diversified leading cancer hospitals and passed the important milestone of 50% of patient enrollment. We have also conserved cash resources and assembled a first class executive team and Board of Directors to execute on our clinical and financial milestones as we prepare for commercialization. I look forward to speaking with the investment community in a few weeks to share our excitement for 2009."

The call will be available live and archived via the Delcath website. In addition, the call can be accessed via telephone; dial-in information will be provided a few days prior to the call.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
2. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
3. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
4. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
5. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
6. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
7. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
8. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
9. Jon R. Wampler Joins Portico Systems Board of Directors
10. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
11. Portico Systems Wins Three Awards in 30 Days
Post Your Comments:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology: